Published in PLoS One on December 11, 2012
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Natural killer cell deficiency. J Allergy Clin Immunol (2013) 1.74
Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. EBioMedicine (2015) 0.86
ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56(dim)CD16(+) and CD56(bright)CD16(dim/-) natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. J Transl Med (2016) 0.84
CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. PLoS One (2016) 0.75
Expression and Functional Role of α7 Nicotinic Receptor in Human Cytokine-stimulated Natural Killer (NK) Cells. J Biol Chem (2016) 0.75
Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol (2008) 7.88
Human natural killer cells. Blood (2008) 7.37
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood (2010) 3.32
Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med (2006) 3.29
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
CD56bright natural killer (NK) cells: an important NK cell subset. Immunology (2009) 2.25
L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med (2005) 2.02
Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol (2006) 2.02
CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol (2007) 1.99
NK cells at the interface between innate and adaptive immunity. Cell Death Differ (2007) 1.83
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
NK cells and immune "memory". J Immunol (2011) 1.66
NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One (2010) 1.59
Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol (1998) 1.55
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol (2004) 1.50
Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 1.42
MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest (2012) 1.39
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol (2005) 1.36
Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest (2012) 1.35
An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol (2008) 1.34
CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol (2010) 1.30
CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol (2011) 1.24
Cytokine regulation of natural killer cell effector functions. Biofactors (2010) 1.13
Analysis of the costimulatory role of IL-2 and IL-15 in initiating proliferation of resting (CD56dim) human NK cells. J Immunol (1996) 0.98
HLA class I deficiency syndrome mimicking Wegener's granulomatosis. Arthritis Rheum (2008) 0.97
TGF-β affects development and differentiation of human natural killer cell subsets. Eur J Immunol (2010) 0.97
Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunol Lett (1999) 0.91
Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors. Mol Immunol (2005) 0.86
Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection. Scand J Immunol (2008) 0.85
Phenotypic studies of natural killer cell subsets in human transporter associated with antigen processing deficiency. PLoS One (2007) 0.83
Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med (2003) 3.31
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol (2006) 1.79
Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol (2013) 1.52
NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol (2004) 1.20
First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol (2014) 1.18
Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev (2007) 0.99
IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood (2013) 0.93
Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol (2006) 0.90
A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease. J Clin Endocrinol Metab (2012) 0.90
Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol (2013) 0.88
[Job's syndrome and miliary tuberculosis]. Medicina (B Aires) (2014) 0.85
[Subcutaneous immunoglobulin. Treatment in chronic inflammatory demyelinating polyradiculo-neuropathy]. Medicina (B Aires) (2016) 0.79
Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol (2003) 0.78
Long-term follow-up of STAT5B deficiency in three argentinian patients: clinical and immunological features. J Clin Immunol (2015) 0.77
Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions. Cancer Immunol Immunother (2013) 0.76
Identification of the first patient with a confirmed mutation of the JAK-STAT system. Pediatr Nephrol (2005) 0.76
Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol (2013) 0.75
Molecular characterization of a novel splice site mutation within the CYBB gene leading to X-linked chronic granulomatous disease. Pediatr Blood Cancer (2005) 0.75
In vitro presentation of gliadin-derived peptides by different cell lines. Clin Chim Acta (2002) 0.75